Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

In the present study, we investigated the interactions between proteasome inhibitor carfilzomib (CFZ) and histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells. Coexposure of cells to minimally lethal concentrations of CFZ with very low concentration of vorinostat resulted in synergistic antiproliferative effects and enhanced apoptosis in Jurkat T-leukemia cells, accompanied with the sharply increased reactive oxygen species (ROS), the striking decrease in the mitochondrial membrane potential (MMP), the increased release of cytochrome c, the enhanced activation of caspase-9 and -3, and the cleavage of PARP. The combined treatment of Jurkat cells pre-treated with ROS scavengers N-acetylcysteine (NAC) significantly blocked the loss of mitochondrial membrane potential, suggesting that ROS generation was a former event of the loss of mitochondrial membrane potential. Furthermore, NAC also resulted in a marked reduction in apoptotic cells, indicating a critical role for increased ROS generation by combined treatment. In addition, combined treatment arrested the cell cycle in G2-M phase. These results imply that CFZ interacted synergistically with vorinostat in Jurkat T-leukemia cells, which raised the possibility that the combination of carfilzomib with vorinostat may represent a novel strategy in treating T-cell Leukemia.

[1]  Yan Liu,et al.  Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK. , 2013, Biomedical and environmental sciences : BES.

[2]  E. Ocio,et al.  Novel generation of agents with proven clinical activity in multiple myeloma. , 2013, Seminars in oncology.

[3]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[4]  A. El-Osta,et al.  Immunomodulatory effects of histone deacetylase inhibitors. , 2013, Current molecular medicine.

[5]  Dona N. Ho,et al.  Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein–Barr Virus , 2013, Molecular Cancer Therapeutics.

[6]  P. Viale,et al.  Histone deacetylase inhibitors: novel agents in cancer treatment. , 2013, Clinical journal of oncology nursing.

[7]  C. Eckert,et al.  Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB , 2013, Clinical Cancer Research.

[8]  Jianmin Yang,et al.  Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro , 2012, Cancer Chemotherapy and Pharmacology.

[9]  J. Grandis,et al.  Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy , 2012, Clinical Cancer Research.

[10]  Derick R. Peterson,et al.  Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[11]  R. Johnstone,et al.  Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. , 2012, Advances in cancer research.

[12]  F. Rassool,et al.  HDAC inhibitors: roles of DNA damage and repair. , 2012, Advances in cancer research.

[13]  J. Friedberg,et al.  Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo , 2011, Molecular Cancer Therapeutics.

[14]  Zhi-xiang Shen,et al.  Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells , 2011, Annals of Hematology.

[15]  W. Guo,et al.  Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. , 2010, Molecular medicine reports.

[16]  J. Friedberg,et al.  The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. , 2010, Blood.

[17]  L. Gordon,et al.  PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells , 2009, Clinical Cancer Research.

[18]  L. Cipak,et al.  Apoptosis induced by 2-acetyl-3-(6-methoxybenzothiazo)-2-yl-amino-acrylonitrile in human leukemia cells involves ROS-mitochondrial mediated death signaling and activation of p38 MAPK. , 2009, Cancer letters.

[19]  F. Yang,et al.  The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis , 2009, Leukemia.

[20]  H. Dombret,et al.  NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. , 2009, Blood.

[21]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[22]  J. Meijerink,et al.  Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences , 2008, Leukemia.

[23]  M. Munsell,et al.  NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. , 2007, Blood.

[24]  S. Grant,et al.  Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors , 2004, Clinical Cancer Research.

[25]  Paul Dent,et al.  The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. , 2003, Blood.